Bedel Financial Consulting’s Biogen BIIB Stock Holding History

Bedel Financial Consulting’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-406	Closed	-$86K	–	270
2022 Q1	$86K	Hold	406	–	–	0.03%	299
2021 Q4	$97K	Hold	406	–	–	0.03%	290
2021 Q3	$115K	Hold	406	–	–	0.04%	249
2021 Q2	$141K	Sell	406 -77	-16%	-$23.3K	0.05%	222
2021 Q1	$135K	Hold	483	–	–	0.05%	217
2020 Q4	$118K	Hold	483	–	–	0.05%	206
2020 Q3	$137K	Hold	483	–	–	0.07%	172
2020 Q2	$129K	Sell	483 -2	-0.4%	-$601	0.07%	170
2020 Q1	$153K	Buy	485 +2	+0.4%	+$607	0.1%	141
2019 Q4	$143K	Buy	483 +10	+2%	+$2.77K	0.08%	174
2019 Q3	$110K	Hold	473	–	–	0.07%	191
2019 Q2	$111K	Hold	473	–	–	0.07%	187
2019 Q1	$112K	Hold	473	–	–	0.07%	180
2018 Q4	$142K	Hold	473	–	–	0.1%	146
2018 Q3	$160K	Hold	473	–	–	0.11%	154
2018 Q2	$137K	Sell	473 -6	-1%	-$1.69K	0.1%	166
2018 Q1	$131K	Buy	+479	New	+$149K	0.1%	169

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bedel Financial Consulting's BIIB Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Biogen (BIIB) in Q2 2022, closing a stake of 406 shares — an estimated $86K sold.

Bedel Financial Consulting first reported a position in BIIB in Q1 2018 and held it in 17 quarters. The position peaked at $160K in Q3 2018. 927 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

Bedel Financial Consulting reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
Bedel Financial Consulting sold 406 Biogen shares in Q2 2022, an estimated $86K.
Bedel Financial Consulting first reported a position in Biogen in Q1 2018 and held it in 17 quarters.
Bedel Financial Consulting's Biogen position peaked at $160K in Q3 2018.
927 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.